ARCA biopharma (NASDAQ: ABIO)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-03 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.230 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of ARCA biopharma (NASDAQ: ABIO) through any online brokerage.
Other companies in ARCA biopharma’s space includes: Virios Therapeutics (NASDAQ:VIRI), Acurx Pharmaceuticals (NASDAQ:ACXP), Synaptogenix (NASDAQ:SNPX), Larimar Therapeutics (NASDAQ:LRMR) and Applied Genetic (NASDAQ:AGTC).
The latest price target for ARCA biopharma (NASDAQ: ABIO) was reported by Dawson James on Wednesday, October 9, 2013. The analyst firm set a price target for 3.75 expecting ABIO to rise to within 12 months (a possible 51.21% upside). 0 analyst firms have reported ratings in the last year.
The stock price for ARCA biopharma (NASDAQ: ABIO) is $2.48 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for ARCA biopharma.
ARCA biopharma’s Q2 earnings are confirmed for Wednesday, August 3, 2022.
There is no upcoming split for ARCA biopharma.
ARCA biopharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.